Skip to content

Microneedling with topical autologous Platelet rich plasma versus intralesional Triamcinolone acetonide in Alopecia Areata

Comparative evaluation of efficacy and safety of combination of microneedling with topical autologous Platelet rich plasma versus Triamcinolone acetonide in Alopecia Areata

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031963
Enrollment
40
Registered
2021-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L638- Other alopecia areata

Interventions

Intervention1: Combination of Microneedling With Topical Autologous Platelet Rich Plasma: Patients in this group will be treated by microneedling technique using dermaroller in combination with topica

Sponsors

Dr Surabhi Dayal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed as Alopecia Areata of the scalp less than or equal to 5 patches and less than or equal to 25 % scalp involvement and who have not taken any treatment for hair loss in the past 3 months and are willing to consent for enrollment in the study

Exclusion criteria

Exclusion criteria: Patients with history of bleeding disorders,on anticoagulant medications,with an active infection at local site,having keloidal tendency, having psoriasis or lichen planus because of risk of Koebner phenomenon or any other dermatological disease,having alopecia totalis or alopecia universalis,who had taken any treatment for hair-loss in the past 3 months,with history of hypersensitivity to formulation used in the study,Severe systemic illness or malignancy,Pregnant and lactating mothers.

Design outcomes

Primary

MeasureTime frame
Decrease in the mean SALT (Severity of Alopecia Areata Tool)scores from the baseline will be compared between the two groups.Timepoint: Baseline,4 weeks,8 weeks,12 weeks and 16 weeks.

Secondary

MeasureTime frame
VISUAL ANALOGUE SCALE: Patients to grade their improvement from 0 to 10 on a 10 point scale as per his/her satisfaction. 7-10: Excellent response. 4-6: Good response. 0-3: Poor response. Timepoint: At the end of 16 weeks

Countries

India

Contacts

Public ContactDr Mani Mehra

Pt B.D. Sharma, PGIMS, Rohtak

surabhidayal7@gmail.com9896205319

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026